0.000
0.00 (-90.00%)
| Penutupan Terdahulu | 0.001 |
| Buka | 0.001 |
| Jumlah Dagangan | 532,915 |
| Purata Dagangan (3B) | 152,991 |
| Modal Pasaran | 246,506,992 |
| Harga / Jualan (P/S) | 0.020 |
| Harga / Buku (P/B) | 18.28 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Oct 2024 - 29 Oct 2024 |
| Margin Keuntungan | -267.19% |
| Margin Operasi (TTM) | -231.44% |
| EPS Cair (TTM) | -1.08 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -53.00% |
| Nisbah Semasa (MRQ) | 0.450 |
| Aliran Tunai Operasi (OCF TTM) | -129.71 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -54.01 M |
| Pulangan Atas Aset (ROA TTM) | -28.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | LumiraDx Limited | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.0 |
| Purata | 0.75 |
|
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| % Dimiliki oleh Orang Dalam | 37.93% |
| % Dimiliki oleh Institusi | 3.37% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |